Navigation Links
FTC Ends Investigation of CVS Caremark
Date:1/12/2012

nd services that differentiate us and benefit consumers," said Larry Merlo, President and Chief Executive Officer of CVS Caremark.  "We remain committed to delivering the best possible pharmacy care by driving down health care costs, expanding consumer access and improving health care outcomes.    

"During the course of this two year investigation, our company cooperated fully with the FTC and provided to the government millions of documents as well as access to numerous members of our management team who participated in voluntary interviews and depositions," said Douglas A. Sgarro, Executive Vice President and Chief Legal Officer of CVS Caremark.  "It is important to note that, at the conclusion of this comprehensive investigation, the FTC made no allegations of antitrust law violations or anti-competitive behavior associated with any of our business practices, products or service offerings."

About CVS Caremark
CVS Caremark is the largest pharmacy health care provider in the United States with integrated offerings across the entire spectrum of pharmacy care. We are uniquely positioned to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including more than 7,300 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor™ program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information ab
'/>"/>

SOURCE CVS Caremark
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
7. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - Panacos,Pharmaceuticals, ... the next generation of antiviral,therapeutic products, today ... that HIV resistant to Protease Inhibitors (PI) ... resistance to the HIV,maturation inhibitor bevirimat in ...
... Taxotere(R) and on three investigational,agents (VEGF Trap, S-1 ... ASCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ ... abstracts,indicative of its oncology commitment have been accepted ... of Clinical Oncology,(ASCO) in Chicago, Illinois (June 1-5, ...
Cached Medicine Technology:Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 2Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
(Date:7/24/2014)... rats bearing human breast tumors, exposure to dim light ... cancer drug tamoxifen, according to data published in ... for Cancer Research. The negative effects of dim light ... a melatonin supplement during the night. , "Resistance to ... receptor-positive breast cancer," said Steven M. Hill, PhD, professor ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap Manchester ... Authority Field on July 26th. For the past four years, the ... the best club teams from around the world to North America ... weeks after its completion, fans – new and old alike – ... in the world compete. Some of these players were already members ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. District Court, ... order for plaintiff medical information covered by the ... to the July 16th Order, U.S. District Judge ... for Fresenius Medical Care the right to receive ...
(Date:7/24/2014)... Association Executives (ASAE) announced its 2014 Power of A ... Society of Anesthesiologists (ASA). , The ASA Global ... Gold Award, one of the top honors from ASAE. ... the world through education on the global anesthesia crisis ... , ASA was also honored with a Power of ...
(Date:7/24/2014)... July 24, 2014 Pools and beaches are ... water can be dangerous, especially for small children, so ... safety. , According to the Centers for Disease Control and ... most at risk for water-related injuries and deaths. It’s important ... around water, so Amica is offering the following tips from ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... book, written by Dr. Vardit Rispler-Chaim of the Department ... Haifa, analyzes attitudes to people with various ... Middle Ages and the modern era. , In the ... and often within broad topics such as religious duties, ...
... focus on issues most critical to health care ... selected as new survey vendor, WASHINGTON, Dec. 12 ... non-profit organization of employer-based,health coalitions, released its 2008 eValue8(TM) ... health care purchasers to compare,the quality and efficiency of ...
... Dec. 12 INVEGA(TM) (paliperidone),Extended-Release Tablets showed ... open-label extension (OLE) study, according to a ... improved or,were stable, on average, over this ... to evaluate the long-term safety of INVEGA, ...
... had harder time fighting gum disease , , WEDNESDAY, ... harder to fight infections, and a weakened immune response ... Boston University researchers. , In experiments with mice infected ... had less ability to battle gum infection than their ...
... and Providers, AUSTIN, Texas, Dec. 12 ... report, U.S. taxpayers are annually defrauded of,about $60 ... health,care providers. A new system developed by S3 ... significant impact on reducing Medicare,and Medicaid fraud with ...
... by the,positive results of the 2007 Monitoring the Future ... in the right direction,with significant declines in overall teen ... for all measured age groups marking steady long-term,reductions in ... MTF, now in its 33rd year, is an ...
Cached Medicine News:Health News:National Business Coalition on Health Releases 2008 eValue8(TM) RFI 2Health News:National Business Coalition on Health Releases 2008 eValue8(TM) RFI 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 2Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 4Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 5Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 6Health News:Obesity Weakens Immune Response 2Health News:Technology can Dramatically Reduce Billions of Dollars in Medicaid, Medicare Fraud 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 4
New!...
... I/A unit for planned ECCE with ... control). Independent irrigation, suction, reflux possible ... surgeon to control all critical functions. ... simultaneously. Preset and actual vacuum level ...
... Anterior and Posterior segment surgeries Vitrectomy-Lensectomy ... Ventury or Peristaltic Linear Aspiration. Interchangeable ... specific cutting action. Easy to read ... Cutting speed-variable from 1- 600 cuts ...
...
Medicine Products: